MRVIHealthcare · BiotechnologyMRVI Stock Forecast: Maravai Lifesciences Holdings, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. hold a median 12-month price target of $6 — -6.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 1 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
MRVI stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Maravai Lifesciences Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Volatility (19): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Maravai Lifesciences Holdings, Inc. — and when they’d sell — is the membership.
MRVI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MRVI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −6.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 May 2026 | Wells Fargo | Maintains | Overweight | $4.50 → $5.50 |
| 15 Dec 2025 | Wells Fargo | Maintains | Overweight | — |
| 12 Aug 2025 | Craig-Hallum | Maintains | Buy | — |
| 12 Aug 2025 | RBC Capital | Maintains | Outperform | — |
| 13 May 2025 | Baird | Maintains | Neutral | — |
| 13 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 25 Mar 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 21 Mar 2025 | UBS | Maintains | Neutral | — |
| 3 Mar 2025 | B of A Securities | Maintains | Buy | — |
| 26 Feb 2025 | Baird | Downgrade | Neutral | — |
| 5 Dec 2024 | Goldman Sachs | Downgrade | Sell | — |
| 14 Nov 2024 | Wolfe Research | Initiates | Peer Perform | — |
| 8 Nov 2024 | Baird | Maintains | Outperform | — |
| 8 Nov 2024 | RBC Capital | Maintains | Outperform | — |
| 8 Nov 2024 | William Blair | Downgrade | Market Perform | — |
| 8 Oct 2024 | Goldman Sachs | Maintains | Neutral | — |
| 27 Aug 2024 | Wells Fargo | Initiates | Overweight | — |
| 16 Aug 2024 | RBC Capital | Reiterates | Outperform | — |
| 13 Aug 2024 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 8 Aug 2024 | Goldman Sachs | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MRVI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Maravai Lifesciences Holdings, Inc. (MRVI) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 28.4×
- Price / sales
- 11.8×
- Price / book
- 4.6×
- EV / EBITDA
- −33.5×
Cheaper than 29% of US stocks
Cheaper than 13% of US stocks
Cheaper than 23% of US stocks
Cheaper than 92% of US stocks
- Revenue growth (YoY)
- 40.5%
- Earnings growth (YoY)
- 40.5%
- Gross margin
- 51.2%
- Operating margin
- 1.1%
- Net margin
- −51.1%
Higher than 84% of US stocks
Higher than 74% of US stocks
Higher than 65% of US stocks
Higher than 50% of US stocks
Higher than 10% of US stocks
- Return on equity
- −41.0%
- Return on assets
- −6.6%
- Dividend yield
- —
Higher than 23% of US stocks
Higher than 29% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MRVI vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MRVI appears on the weeks it earns a place.
Frequently asked questions about MRVI stock
What is the MRVI stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Maravai Lifesciences Holdings, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MRVI stock a buy right now?
Of the 8 analysts covering Maravai Lifesciences Holdings, Inc., 5 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maravai Lifesciences Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MRVI?
As at 1 Aug 2026, Maravai Lifesciences Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
Will MRVI stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies -6.5% from the last close, and Ticker Nerd's factor model ranks Maravai Lifesciences Holdings, Inc. 88 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MRVI stock forecast for 2030?
No analyst covering Maravai Lifesciences Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MRVI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7 over the next 12 months.
How has MRVI stock performed over the past year?
Maravai Lifesciences Holdings, Inc. returned +189.2% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Maravai Lifesciences Holdings, Inc. do?
Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development.
About Maravai Lifesciences Holdings, Inc.
Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development. The company's main are the production of nucleic acids and biologics, which are essential components in fields such as drug development, diagnostics, and molecular testing. Maravai is deeply involved in supplying innovative solutions for the synthesis and modification of nucleic acids, enabling breakthroughs in messenger RNA (mRNA) technology, a key area in the development of vaccines and therapies. The company's operations are integral to various industries where precision and cutting-edge biological research are paramount. Its contributions have been particularly impactful in accelerating the development of vaccines and treatments in response to the global demand for advanced biopharmaceutical solutions. With a strong commitment to supporting scientific innovation, Maravai Lifesciences Holdings Inc. holds a significant role in the life sciences market, providing foundational tools that empower researchers and healthcare institutions worldwide to achieve advancements in health and medicine.
CEO Mr. Bernd Brust · 416 employees · United States · https://www.maravai.com